UNASSIGNED: @entity2114 is a Gram negative opportunistic @entity1 pathogen that causes a severe @entity55 known as @entity4502 . Notably, in the @entity1 host, the organism is believed to replicate solely within an intracellular compartment, predominantly within pulmonary macrophages. Consequently, successful therapy is predicated on antimicrobials penetrating into this intracellular growth niche. However, standard antimicrobial susceptibility testing methods solely test for extracellular growth inhibition. Here we make use of a high throughput assay to characterize intracellular growth inhibition activity of known antimicrobials. For select antimicrobials, high resolution dose-response analysis was then performed to characterize and compare activity in both macrophage @entity281 and axenic growth assays. Results support superiority of several classes of non-polar antimicrobials in abrogating intracellular growth. Importantly, our assay results show excellent correlation with prior clinical observations of antimicrobial efficacy. Furthermore, we also show the applicability of high throughput automation to two and three dimensional synergy testing. High resolution isocontour isobolograms provide in vitro support for specific combination antimicrobial therapy. Taken together, findings suggest that high throughput screening technology may be successfully applied to identify and characterize antimicrobials that target bacterial pathogens that make use of an intracellular growth niche.

High throughput intracellular antimicrobial susceptibility testing of XXXX .

@entity1 :: ('9606', 'Species') :: ['human'] @entity4502 :: ('MESH:D007877', 'Disease') :: ["Legionnaires' disease"] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity2114 :: ('446', 'Species') :: ['Legionella pneumophila']
@entity2114 :: (446,Species) :: ['Legionella pneumophila']
